Phytocom Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 23-12-2024
- Paid Up Capital ₹ 0.10 M
as on 23-12-2024
- Company Age 7 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 17.71%
(FY 2023)
- Profit -88.34%
(FY 2023)
- Ebitda -159.28%
(FY 2023)
- Net Worth -46.93%
(FY 2023)
- Total Assets 94.26%
(FY 2023)
About Phytocom Pharmaceuticals
The Company is engaged in the Travel And Hospitality Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Chidambarathanu Pillai and Ramachandran Santhosh serve as directors at the Company.
- CIN/LLPIN
U93090KL2017PTC050331
- Company No.
050331
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Sep 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Thiruvananthapuram, Kerala, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Phytocom Pharmaceuticals Private Limited offer?
Phytocom Pharmaceuticals Private Limited offers a wide range of products and services, including Bird Food, Poultry & Animal Food, Pet Food, Fish Foods, Wood, Plywood, Veneer & Laminates, Hardwood.
Who are the key members and board of directors at Phytocom Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Chidambarathanu Pillai  | Director | 04-Sep-2017 | Current |
| Ramachandran Santhosh | Director | 04-Sep-2017 | Current |
Financial Performance of Phytocom Pharmaceuticals.
Phytocom Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 17.71% increase. The company also saw a substantial fall in profitability, with a 88.34% decrease in profit. The company's net worth observed a substantial decline by a decrease of 46.93%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Phytocom Pharmaceuticals?
Unlock access to Phytocom Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Phytocom Pharmaceuticals?
Unlock and access historical data on people associated with Phytocom Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Phytocom Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Phytocom Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
